A systematic review 1 including 8 studies with a total of 520 subjects was abstracted in DARE. There was no difference in oesophageal re-bleeding (5 trials, RR 1.05, 95% CI 0.67 to 1.64) or mortality (7 studies, RR 0.99, 95% CI 0.68 to 1.44). The analysis of adverse events found no significant differences in perforation, infection, posthemostasis ulcer bleeding, or cardiopulmonary arrest, but the incidence of oesophageal stricture formation was found to be higher with combination therapy (8.9) than with EBL alone (0.38%), and this difference was statistically significant.
Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison) and by limitations in study quality.
Primary/Secondary Keywords